Home
About
Overview
Sharing Data
ORCID
Help
History (1)
Donanemab, another anti-Alzheimer's drug with risk and uncertain benefit.
See All Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Donanemab, another anti-Alzheimer's drug with risk and uncertain benefit.
Donanemab, another anti-Alzheimer's drug with risk and uncertain benefit. Ageing Res Rev. 2024 Aug; 99:102348.
View in:
PubMed
subject areas
Alzheimer Disease
Antibodies, Monoclonal, Humanized
Humans
authors with profiles
George Perry